The inhaled vaccine being researched by CanSino is based on its Convidecia adenovirus vector vaccine for Covid-19. -CANSINOTECH.COM
BEIJING (China Daily/Asia News Network): An inhaled Covid-19 vaccine developed by Chinese firm CanSino Biologics has entered late-stage clinical trials, with data suggesting it is eligible to apply for emergency use in China, the company's chief scientist said.
Zhu Tao, a member of the Chinese People's Political Consultative Conference National Committee, said future Covid-19 vaccination may replace the "jab" with a "huff", and that the procedure is as simple as "sipping a cup of coffee".
Celebrate Merdeka with 50% Off!
T&C applies.
![](https://cdn.thestar.com.my/Themes/img/sub_paywall_TSM.webp)